DZ Bank AG reiterated their neutral rating on shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (NASDAQ:STDAF) in a research report report published on Thursday morning.

Separately, Zacks Investment Research cut shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) from a strong-buy rating to a hold rating in a research report on Wednesday, February 15th.

STADA ARZNEIMITTEL NP (NASDAQ:STDAF) opened at 68.30 on Thursday. The company’s 50-day moving average price is $61.95 and its 200-day moving average price is $54.49. The firm has a market cap of $4.25 billion and a price-to-earnings ratio of 46.49. STADA ARZNEIMITTEL NP has a one year low of $41.70 and a one year high of $68.30.

COPYRIGHT VIOLATION NOTICE: “DZ Bank AG Reaffirms “Neutral” Rating for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (STDAF)” was reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at http://www.mareainformativa.com/stada-arzneimittel-vanregd-vinkuliert-stdaf-clasificacion-reitero-el-dz-bank-ag/108218/.

5 Day Chart for NASDAQ:STDAF

Receive News & Stock Ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) and related stocks with our FREE daily email newsletter.